Trial Profile
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs FP 025 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Foresee Pharmaceuticals
- 17 Dec 2020 Results published in the Clinical Drug Investigation
- 26 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
- 26 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.